TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Overview
Source: Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Atypical Chronic Myeloid Leukemia
The optimal treatment of aCML is uncertain because of the rare incidence of this chronic leukemic disorder. Treatment with hydroxyurea may lead to short-lived partial remissions of 2 to 4 months in duration.[4] Atypical CML appears to respond poorly to treatment with interferon alfa.[4]
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice